Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimuningshen Koufuye is a Traditional Chinese Medicine (TCM) oral liquid formulation primarily indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and tic disorders in children and adolescents. The formulation is composed of several botanical and animal-derived ingredients, including *Rehmannia glutinosa* (Di Huang), *Ostrea gigas* (Mu Li), *Alisma plantago-aquatica* (Ze Xie), *Schisandra chinensis* (Wu Wei Zi), *Scrophularia ningpoensis* (Xuan Shen), and *Scutellaria baicalensis* (Huang Qin). In the context of TCM theory, it is designed to nourish liver and kidney yin, suppress hyperactive liver yang, and calm the spirit (Ning Shen). Clinical research, including studies conducted at Beijing Anding Hospital, has evaluated its efficacy as both a monotherapy and an adjunctive treatment alongside conventional stimulants like methylphenidate or non-stimulants like atomoxetine. Pharmacologically, it is believed to modulate the balance of neurotransmitters in the central nervous system, specifically targeting the dopaminergic and noradrenergic systems to improve attention and reduce hyperactivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dimuningshen Koufuye.